Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Medtronic
McKesson
Cerilliant
UBS
Merck
Mallinckrodt
Baxter
AstraZeneca

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,747,019

« Back to Dashboard

Which drugs does patent 6,747,019 protect, and when does it expire?

Patent 6,747,019 protects PREFEST and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.
Summary for Patent: 6,747,019
Title: Low dose estrogen interrupted hormone replacement therapy
Abstract:A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17.beta.-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 .mu.g per day of norgestimate.
Inventor(s): Casper; Robert F. (Toronto, CA), Shangold; Gary A. (Califon, NJ), Ausmanas; Militza K. (Lake Forest, IL)
Assignee: Jencap Research, Ltd. (Toronto, CA) Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Application Number:10/134,455
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 6,747,019

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Womens PREFEST estradiol; norgestimate TABLET;ORAL 021040-001 Oct 22, 1999 DISCN Yes No ➤ Sign Up ➤ Sign Up HORMONE REPLACEMENT ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,747,019

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,078,394 Low dose estrogen interrupted hormone replacement therapy ➤ Sign Up
7,320,970 Low dose estrogen interrupted hormone replacement therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Argus Health
Julphar
Queensland Health
UBS
Medtronic
Fuji
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.